

PRESS RELEASE

Screening medium recovers resistant organisms that could cause serious infections due to prostate biopsies.



Photo by Teresa Rodil

Santa Maria, California, April 9, 2013

Microbial antibiotic resistance has increased significantly among gram-negative bacilli in recent years and colonization of the gastrointestinal tract by resistant microorganisms serves as a reservoir for potential clinical infection. This can be dangerous for patients undergoing transrectal prostate biopsy in the histological diagnosis of prostate carcinoma. Approximately 800,000 biopsies are performed in the U.S. each year and complications from this procedure include urinary tract infections, prostatitis, and sepsis. In general, the procedure usually follows antibiotic prophylaxes with fluoroquinolones and patients harboring fluoroquinolone-resistant microorganisms are at greater risk of contracting post-procedural infection.

The most common organism responsible for bacterial infection and clinical complication following transrectal prostate biopsy is *Escherichia coli*. Consequently, selective broth pre-enrichment, followed by selective culture on solid agar, is a useful tool in identifying patients colonized with

1430 West McCoy Lane, Santa Maria, California, USA ~ Ph: (805) 346-2766, Fx: (805) 346-2760

Website: www.HardyDiagnostics.com ~ Email: Sales@HardyDiagnostics.com

California ~ Washington ~ Utah ~ Arizona ~ Texas ~ Ohio ~ New York ~ Florida



resistant microorganisms prior to biopsy. Diagnosis of patients colonized with resistant microorganism at least 48 hours in advance of transrectal prostate biopsy may allow physicians time to tailor appropriate antibiotics for better patient management and clinical outcome.

Hardy Diagnostics culture media for detecting fluoroquinolone-resistant microorganisms are meant to be used for the selective pre-enrichment and isolation of fluoroquinolone-resistant enteric bacteria. Liquid media containing ciprofloxacin are meant to be used with the corresponding solid agar medium containing the same concentration of antibiotic for best performance. Ciprofloxacin is added to the media at either 10μg/ml or 1μg/ml for the selective isolation of fluoroquinolone-resistant microorganisms. BHI Broth with Ciprofloxacin, 10μg/ml (Cat.no. K258) should only be used with MacConkey Agar with Ciprofloxacin, 10μg/ml (Cat. no. G258) and BHI Broth with Ciprofloxacin, 1μg/ml (Cat. no. K358) should only be used with MacConkey Agar with Ciprofloxacin, 1μg/ml (Cat. no. G358).

ABOUT HARDY DIAGNOSTICS

Hardy Diagnostics, an FDA licensed manufacturer of medical devices for microbiological testing with an ISO 13485 certified Quality Management System. The company manufactures over 3,500 products for the culture and identification of bacteria and fungi from its California and Ohio manufacturing facilities. Headquartered in Santa Maria, CA, Hardy Diagnostics services over 8,000 laboratories throughout the nation.

The company, which is now employee owned, was founded in 1980 by Jay Hardy, a Clinical Laboratory Scientist from Santa Barbara, CA. Today, Hardy Diagnostics maintains eight distribution centers throughout the U.S. and exports products to over 30 foreign distributors.

The company's mission is to partner with its laboratory customers to prevent and diagnose disease. For more information on products and services and a complete profile on the company's history, visit www.HardyDiagnostics.com.

Contact Information:

Contact Person: Christopher Catani

Company Name: HARDY DIAGNOSTICS

Address: 1430 West McCoy Lane, Santa Maria, CA 93455

Phone Number: (805) 346-2766, Ext: 5696

Fax Number: (805) 928-2950

Email Address: <u>CataniC@HardyDiagnostics.com</u> Company Website: <u>www.HardyDiagnostics.com</u>



04092013kdp